Tofacitinib overcomes an IFNγ‐induced decrease in NK cell‐mediated cytotoxicity via the regulation of immune‐related molecules in LC‐2/ad

Abstract Background Immune checkpoint inhibitors targeting the programmed cell death‐1 (PD‐1)/PD‐1 ligand 1 (PD‐L1) axis have shown promising results in patients with nonsmall cell lung cancer (NSCLC). One major PD‐L1 inducer is IFNγ, which is secreted by T cells and NK cells. Importantly, IFNγ‐indu...

Full description

Bibliographic Details

Published in:	Thoracic Cancer
Main Authors:	Riki Okita, Katsuhiko Shimizu, Yuji Nojima, Shinsuke Saisho, Masao Nakata
Format:	Article
Language:	English
Published:	Wiley 2021-03-01
Subjects:	IFNγ JAK‐STAT pathway NK cell nonsmall cell lung cancer (NSCLC) tofacitinib
Online Access:	https://doi.org/10.1111/1759-7714.13847